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Summary
 
Multiple sclerosis is an autoimmune disease thought to be mediated by CD4
 
1
 
 T helper cells
(Th). Experimental autoimmune encephalomyelitis is a rodent model of multiple sclerosis and
has been used extensively to explore a variety of immunotherapies using soluble protein or
peptide antigens. The underlying mechanisms of such therapy have been attributed to induc-
tion of T cell anergy, a switch in Th1 to Th2 responses, or peripheral deletion of autoreactive
T cells. In this study, we have developed transgenic mice expressing a T cell receptor (TCR)
specific for the NH
 
2
 
-terminal peptide Ac1-11 of the autoantigen myelin basic protein to ex-
plore the mechanism of soluble peptide therapy. T cells from these mice are highly skewed to-
ward the CD4 population and have an abnormal thymic architecture, a phenomenon found in
other TCR transgenic mice that exhibit a highly skewed CD4/CD8 ratio. Soluble Ac1-11 or
the analogues Ac1-11[4A] or Ac1-11[4Y] (which bind to the major histocompatibility com-
plex [MHC] class II molecule I-A
 
u
 
 with increasing affinities) given intravenously activates T cells,
rendering cells hyperresponsive in vitro for at least two days after injection. Concomitantly,
T cells apoptose in the periphery, the degree of which correlates with the affinity of the peptide
for the MHC. In addition, a shift in the T helper phenotype of the surviving T cells occurs
such that the low affinity peptide, Ac1-11, induces primarily a Th1 response, whereas the high-
est affinity peptide, Ac1-11[4Y], induces primarily a Th2 type response. These data show that
both the nature and the presumed number of the peptide–MHC complexes formed during
specific peptide therapy affect both the degree of peripheral programmed cell death as well as
the outcome of the T helper subset response in vivo, leading to amelioration of disease.
 
I
 
n an immune response, encounter with a foreign antigen
may trigger an inflammatory cell–mediated or a primarily
humoral response, each of which is characterized by a sub-
set of CD4
 
1
 
 T helper cells, Th1 and Th2, respectively.
These T cell subsets secrete a distinct set of cytokines which
influence cytolytic function and antibody isotype produc-
tion (1–3). Many organ-specific autoimmune diseases are
thought to be initiated by Th1 responses, whereas protec-
tion, or recovery, is thought to be mediated by Th2 re-
sponses (4). Experimental autoimmune encephalomyelitis
(EAE)
 
1
 
 is a Th1-mediated rodent model of multiple sclero-
sis that can be induced with the NH
 
2
 
-terminal peptide of
myelin basic protein (MBP) Ac1-11, in PL/J or (PL/J 
 
3
 
SJL/J)F1 mice (5). EAE has been successfully treated with
the immunodominant epitope of MBP, Ac1-11, as well as
analogues in which position four is changed from the native
lysine to an alanine (Ac1-11[4A]) or tyrosine (Ac1-11[4Y])
(6–9). Ac1-11[4A] and Ac1-11[4Y] bind to the MHC with
 
z
 
50 and 1,500 times higher affinity than does Ac1-11, and
both peptides stimulate most Ac1-11–specific T cells more
efficiently than does Ac1-11 (10, 11). The affinities of these
peptides for I-A
 
u
 
 correlate with the half-lives of each of the
peptides complexed to I-A
 
u
 
; Ac1-11/I-A
 
u
 
 has an immea-
surably short half-life, Ac1-11[4A] has a half-life of 
 
z
 
10
min, and Ac1-11[4Y]/I-A
 
u
 
 can be detected for as long as
10 h (6, 12). The efficacy of treatment of EAE with these
three peptides correlates with the affinity of the peptides
for I-A
 
u
 
. The mechanism of this treatment may be due to
anergy, deletion, a switch in Th subset, or a combination
of these phenomena (6–9, 13, 14). In other systems, solu-
ble superantigen or peptide has been shown to activate
 
1
 
Abbreviations used in this paper: 
 
AICD, activation-induced cell death;
APL, altered peptide ligands; DP, double positive; EAE, experimental au-
toimmune encephalomyelitis; FasL, Fas ligand; HA, hemagglutinin; LT,
lymphotoxin; MBP, myelin basic protein; mTNF, membrane-bound
TNF-
 
a
 
; SP, single positive; TNFR, TNF receptor.
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T cells whose initial expansion is followed by massive dele-
tion (15–17), whereas administration of soluble antigen has
been shown to induce Th2 type responses (18–21).
To explore more fully the mechanism of peptide therapy
in EAE, we developed transgenic mice expressing a TCR
specific for Ac1-11 and restricted to I-A
 
u
 
, which was de-
rived from an encephalitogenic T cell clone (22). In two
lines of transgenic mice that were established, the CD4/
CD8 ratio is increased at least fivefold, and at least 60% of
CD4
 
1
 
 T cells express the Ac1-11–specific 
 
ab
 
-TCR. In-
jection of Ac1-11, Ac1-11[4A], or Ac1-11[4Y] into TCR
transgenic mice induces thymic deletion and peripheral ac-
tivation and apoptosis, the degree of which correlates di-
rectly with the affinity of the peptide for I-A
 
u
 
.
 
Materials and Methods
 
Mice.
 
DNA encoding a genomic construct was derived by
amplifying cDNA from the 1934.4 hybridoma, which expresses
V
 
a
 
4 and V
 
b
 
8.2 (10), and slotting the cDNAs into genomic shut-
tle vectors for the 
 
a
 
 and 
 
b
 
 chains as described (23). Transgenic
mice were established in (B10.S 
 
3
 
 SJL/J)F1 embryos by using
standard techniques (24). Two founders were backcrossed to PL/J
mice (purchased from Jackson Laboratories, Bar Harbor, ME)
several times. Mice used in these experiments were backcrossed at
least two times to PL/J (Jackson Laboratories), and no differences
were observed between generations N2 and N6. A few experi-
ments were performed using TCR transgenic mice backcrossed one
or two times to B10.PL (Jackson Laboratories). TCR transgenic lines
2B4 and 5C.C7, both specific for cytochrome c and I-E
 
k
 
, were
provided by Dr. Yueh-hsiu Chien (Stanford University, Stanford,
CA), and TCR transgenic line D011.10, specific for ovalbumin and
I-A
 
d
 
, was provided by Dr. Anne O’Garra (DNAX Research Insti-
tute, Palo Alto, CA). TCR transgenic mice were also backcrossed
onto mice homozygous for targeted disruption of the IL-4 gene (25).
 
Peptides.
 
Peptides were synthesized using Fmoc chemistry on
a peptide synthesizer (model 431A; Applied Biosystems, Foster
City, CA) and purified by HPLC to 
 
.
 
95% pure. Sequence com-
position was confirmed by amino acid analysis, and molecular weight
was confirmed by mass spectrometry by the University of Cali-
fornia at San Francisco Mass Spectrometry Facility. The sequences
of the peptides are as follows: Ac1-11, Ac-ASQKRPSQRHG;
Ac1-11[4A], Ac-ASQARPSQRHG; Ac1-11[4Y], Ac-ASQYRP-
SQRHG. Peptides were dissolved in PBS and injected intrave-
nously into TCR transgenic mice 4–10-wk-old in volumes 
 
,
 
200
 
m
 
l. Mice were killed at various times after injection, and the phe-
notype and functional state of cells from the thymus, lymph nodes
(inguinal, popliteal, brachial, axillary, cervical, and mesenteric), and
spleen were ascertained.
 
Antibodies.
 
TCR expression was ascertained by staining with
F23.2, an antibody specific for V
 
b
 
8.2 (26), and counterstaining
with a biotinylated goat anti–mouse IgG (CALTAG Labs., South
San Francisco, CA). T cells were assayed for expression of CD69,
CD25, CD62L, CD44, and CD45RB using biotinylated antibodies
(PharMingen, San Diego, CA) and counterstaining with strepta-
vidin-conjugated Texas red (Boehringer Mannheim, Indianapo-
lis, IN) or streptavidin-conjugated phycoerythrin (CALTAG Labs.).
The number of CD4
 
1
 
 and CD8
 
1
 
 T cell subpopulations were as-
certained using phycoerythrin- and FITC-conjugated antibodies
(CALTAG Labs.), respectively, while the number of macrophages
was determined with a biotinylated antibody specific for Mac-1
(CALTAG Labs.). The number of B cells was determined by stain-
ing with a phycoerythrin-conjugated antibody to B220 (Phar-
Mingen) or FITC-conjugated 40.N, an antibody specific for I-A
 
k,u
 
(27). Cells stained with these antibodies were analyzed for median
fluorescence and percentage of expression by flow cytometry as
described (28). Detection of Fas ligand (FasL), membrane-bound
TNF-
 
a
 
 (mTNF), and lymphotoxin (LT)-
 
ab
 
 was determined by in-
cubating cells with recombinant Fas/Fc, TNF receptor (TNFR)/Fc,
and LT-
 
b
 
R/Fc fusion proteins (Fas/Fc and TNFR/Fc proteins
were a gift of D. Lynch, Immunex Corp., Seattle, WA; and
LT-
 
b
 
R/Fc protein was a gift of R. Ettinger (Stanford University,
Stanford, CA), C.M. Ambrose and C. Hession (Biogen Corp., Bos-
ton, MA), and W. Force and C. Ware (La Jolla Institute for Al-
lergy and Immunology, La Jolla, CA), and counterstaining with a
biotinylated mouse anti–human IgG Fc-specific antibody (Jack-
son ImmunoResearch Labs., Inc., West Grove, PA) and visual-
ized with streptavidin–Texas red. Anti–IL-4 antibody BVD-4
was used to block endogenous IL-4 production by naive T cells
stimulated in vitro (29). Anti–B7-2 antibody GL-1 was adminis-
tered in vivo to block co-stimulatory activity by B7-2 and was
purchased from PharMingen (30). IL-4 was provided by Dr.
Anne O’Garra (DNAX Research Institute). Anti–class II anti-
body 10-3.6 was used to block peptide-MHC-TCR interactions
in in vitro cultures (31).
 
T Cell Stimulation In Vitro.
 
To determine the in vitro prolif-
erative response, 2.5 
 
3
 
 10
 
4
 
 lymph node cells from PBS- or pep-
tide-injected TCR transgenic mice were incubated with 3 
 
3
 
 10
 
5
 
irradiated (30 Gy) nontransgenic syngeneic splenocytes, or 3 
 
3
 
10
 
5
 
 splenocytes from naive or peptide-injected TCR transgenic
mice were incubated in flat-bottom 96-well plates in 0.2 ml/well
of RPMI 1640 medium (GIBCO BRL, Gaithersburg, MD) sup-
plemented with 5 
 
3
 
 10
 
2
 
5
 
 M 2-mercaptoethanol, pencillin, strep-
tomycin, 200 mM glutamine, and 5% heat-inactivated fetal bo-
vine serum. 24–48 h later, cultures were pulsed with 0.5 
 
m
 
Ci
[
 
3
 
H]thymidine per well for 18–24 h, harvested, and counted. Cy-
tokine profiles were assayed by culturing 10
 
5
 
 lymph node cells
with 3 
 
3
 
 10
 
5
 
 irradiated (30 Gy) nontransgenic syngeneic spleno-
cytes or 3 
 
3
 
 10
 
5
 
 splenocytes from PBS-injected or peptide-injected
TCR transgenic mice in 96-well round-bottom plates for 48 h.
Cultures were frozen at 
 
2
 
80
 
8
 
C, and the levels of IL-2, IL-4, IL-10,
and IFN-
 
g
 
 in the supernatants were determined by ELISA using
paired antibodies purchased from PharMingen. Fas, FasL, mTNF,
and LT-
 
ab
 
 levels were determined on splenocytes derived from ei-
ther PBS- or peptide-injected Ac1-11–specific or influenza hemag-
glutinin–specific TCR transgenic mice, which were cultured in
T162 tissue culture flasks at 10–100 
 
m
 
M Ac1-11 or 0.2 
 
m
 
g/ml
hemagglutinin peptide 126-138, respectively, in complete medium
for 48 h.
 
Detection of Apoptosis.
 
Inguinal and brachial lymph nodes from
PBS-injected or peptide-injected MBP-specific TCR transgenic
mice were fixed at least 24 h in 3.7% formaldehyde in PBS and
embedded in paraffin. The TUNEL reaction, which detects
nicked DNA in nuclei of apoptotic cells, was performed as de-
scribed (32) except that diaminobenzidine was used as the sub-
strate for the streptavidin-conjugated peroxidase.
 
Thymic Architecture.
 
Thymi from naive or peptide-injected
mice were fixed in 3.7% formaldehyde for 24 h and embedded in
paraffin. Sections were first stained with hematoxylin and eosin to
assess thymic architecture. Specific staining for medullary epithe-
lial cells was determined as described using frozen sections (33).
In brief, tissue was frozen in Tissue Tek, and 5 
 
m
 
m sections were
cut and placed on gelatin-coated slides and air dried. Next, sec-
tions were dipped in acetone, air dried, and immersed in PBS 
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containing 0.5% horse serum and 0.01% Tween-20. Sections
were then incubated with antibody ERTR5, washed, and incu-
bated with an anti–Ig antibody conjugated to horseradish peroxi-
dase. After washing, ERTR5
 
1
 
 cells were visualized by incubating
sections with diaminobenzidine. Sections were then rinsed,
mounted, and photographed.
 
Results
 
A High CD4/CD8 Ratio Results in Abnormal Thymic Ar-
chitecture.
 
Two lines of transgenic mice were established.
In one line, both the 
 
a
 
 and 
 
b
 
 transgenes were integrated
onto the X chromosome. In this line, 
 
.
 
90% of T cells from
males expressed V
 
b
 
8.2, whereas only 50% of T cells from
females express V
 
b
 
8.2, presumably due to random inacti-
vation of the X chromosome on a cell by cell basis. In
males, the CD4/CD8 ratio is increased by 
 
z
 
15-fold over
that of normal, whereas in females, the CD4/CD8 ratio is
 
z
 
1.5-fold over that of normal. In the second line, the
transgenes were integrated onto an autosomal chromo-
some, and 
 
.
 
90% of T cells from both males and females
express V
 
b
 
8.2. The CD4/CD8 ratio in the second line is
increased by fivefold over that of normal. In males of the
first line and all mice of the second line, at least 60% of
CD4
 
1
 
 T cells express the Ac1-11–specific 
 
ab
 
-TCR as
judged by the number of CD4
 
1
 
 T cells that flux calcium
in response to splenocytes presenting Ac1-11 (data not
shown). Lymph node or spleen cells from either line when
cultured in vitro with Ac1-11, Ac1-11[4A], or Ac1-11[4Y]
spontaneously proliferate (data not shown). Routine hema-
toxylin and eosin staining of sections of the thymus from
both lines of our TCR transgenic mice revealed that the
thymi do not have a clearly defined cortex and medulla, an
observation first noted in two other independent Ac1-11–
specific TCR transgenic mice (33a). Interestingly, the thy-
mus from the line with a higher CD4/CD8 ratio has a
more severe defect than the line with a lower CD4/CD8
ratio. Specific staining of sections from thymi from the sec-
ond MBP-specific TCR transgenic line that has a lower
CD4/CD8 ratio shows that medullary epithelial cells are
scattered throughout the thymus (Fig. 1). The cortex has a
decreased size, while macrophage and dendritic cell popu-
lations appear normal (data not shown). To determine
whether this defect was specific to these particular MBP-
specific TCR transgenic mouse lines, we examined whether
other class II–restricted TCR transgenic lines that have a
high CD4/CD8 ratio have abnormal thymic architecture. All
three different TCR transgenic lines examined so far, 2B4
(34) and 5C.C7 (35), both cytochrome c-specific and I-E
 
k
 
–
restricted, and DO11.10 (36), specific for ovalbumin pep-
tide 323-339 and restricted to I-A
 
d
 
, show a similar defect
when examined by hematoxylin and eosin stains (data not
shown and Table 1). These data suggest that a normal med-
ullary and cortical epithelial architecture is disrupted by the
increased numbers of single positive (SP) and/or decreased
numbers of double positive (DP) cells found in these TCR
transgenic mice.
 
Soluble Ac1-11, Ac1-11[4A], and Ac1-11[4Y] Induce Thy-
mic Apoptosis.
 
A single large dose of Ac1-11, Ac1-11[4A],
or Ac1-11[4Y] induced varying degrees of deletion of
CD4
 
1
 
CD8
 
1
 
 DP thymocytes (data not shown). 4 h after in-
jection of 2.4 mg of peptide, there was no difference in the
proportion of CD4
 
1
 
 SP, DP, double negative, or CD8
 
1
 
SP cells; by 24 h, however, the number of DP cells after
injection of peptide was reduced 80% by Ac1-11[4Y],
50–75% by Ac1-11[4A], and 25–50% by Ac1-11 (data not
shown). By 6 d after injection of peptide, the total number
of thymocytes was reduced up to 10-fold after injection of
Ac1-11[4Y], two- to fivefold with Ac1-11[4A], and up to
twofold with Ac1-11. A single dose of 240 
 
m
 
g of peptide
induced similar profiles (data not shown). These results
show that despite the abnormal thymic architecture, thy-
mic T cell deletion can occur normally; similar results have
been shown for the DO11.10 and 2B4 TCR transgenic
models (36, 37).
 
Soluble Peptide Induces Peripheral T Cell Activation.
 
As in
the thymus, the affinity of the peptide for the MHC plays
Figure 1. Thymic architecture of MBP-specific TCR transgenic mice
and a normal nontransgenic littermate, as illustrated by ERTR5, an anti-
body that is specific for medullary epithelium. (A) Thymus from a MBP-
specific TCR transgenic. (B) Thymus from a nontransgenic littermate.
Thymi were from the MBP-specific TCR transgenic line that has a CD4/
CD8 ratio of z5:1 and a less pronounced thymic defect than the line
with the higher CD4/CD8 ratio. Mice were (PL/J 3 B10.PL)F1. c, cor-
tex; m, medulla. 
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an important role in the periphery in regulating the devel-
opment of mature, naive T cells. After intravenous injection
of PBS or peptide, cells from lymph nodes were pooled
and analyzed by flow cytometry for expression of TCR
and T cell activation and memory markers. Table 2 sum-
marizes the median fluorescence intensity of these markers
on CD4
 
1
 
V
 
b
 
8.2
 
1
 
 T cells. Within 4 h after injection of
2.4 mg of Ac1-11, Ac1-11[4A], or Ac1-11[4Y], TCR ex-
pression, as measured by expression of V
 
b
 
8.2, was down-
regulated by about threefold in 
 
z
 
80% of CD4
 
1
 
 T cells
from Ac1-11[4Y]–treated mice, about twofold in Ac1-
11[4A]–treated mice, and not at all in Ac1-11–treated
mice. TCR expression of cells from Ac1-11[4A]–injected
mice returned to normal within 24 h, while TCR expres-
sion of cells from Ac1-11[4Y]–injected mice remained
downregulated at 24 h but returned to almost normal by
day 2.
CD69, an early activation marker, and CD25, the alpha
chain of the IL-2 receptor, were upregulated on 
 
z
 
80% of
CD4
 
1
 
 T cells in the periphery within 4 h and remained
high for at least 24 h (Table 2). CD62L, or L-selectin, a
homing receptor that is expressed at high levels on naive T
cells, was downregulated within 4 h on 
 
z
 
80% of CD4
 
1
 
 T
cells and remained low for at least 24 h. By 72 h, however,
most T cells from peptide-injected mice had upregulated
CD62L to levels similar to those found in naive mice.
CD44, a marker of memory T cells, was unchanged at 4 h
after injection, but by 24 h it was upregulated approxi-
mately threefold over that expressed by T cells from PBS-
injected mice (Table 2). Cells from Ac1-11[4Y]–injected
mice consistently expressed slightly lower levels of CD44 at
6 d after injection. No significant changes were detected in
the level of expression of CD45RB, another putative naive
cell marker, at any time point (data not shown). Four daily
injections of any of the three peptides induced high expres-
sion of CD44, whereas CD62L and CD45RB remained
high at day 6 after the first injection (data not shown). B
cells upregulated the co-stimulation molecule B7-2, but not
B7-1, within 24 h, and the expression level of the co-stim-
ulation molecule B7-2 on B cells correlated with the affinity
of the peptide (data not shown). In addition, macrophages,
but not B cells, from peptide-injected mice upregulated
B7-1 (data not shown). Thus, soluble peptide induces T
cell activation, and the degree and length of the activated
state as measured by CD25, CD69, and CD62L depended
on the affinity of the peptide for the MHC.
Table 1. Characteristics of Class II–restricted TCR Transgenic Mice
HNT(15) D011.10(16) MBP-1 MBP-2 2B4(33) 5C.C7(31)
Peptide* HA126-138 OVA323-339 Ac1-11 Ac1-11 cyt. c cyt. c
84-103 84-103
Restriction‡ I-Ad I-Ad I-Au I-Au I-Ek I-Ek
CD4/Cd8§ 3:1 7:1 6–10:1 15–25:1 9–13:1 15–20:1
Thymic
abnormalityi None Mild Moderate Severe Severe Severe
Peripheral
AICD¶ Yes Yes Yes Yes Yes Yes
Decline in
No. T cells** Yes Yes No No Yes Yes
Th subset
Low dose‡‡ nd Th1 and Th 2¶¶, *** Th1 Th1 nd nd
High dose§§ nd Th2 Th2 Th2 nd nd
Backgroundii B10.D2 BALB/c PL/J PL/J B10.BR B10.A
MBP-1 refers to the Ac1-11–specific TCR transgenic line in which the a and b transgenes are integrated autosomally. MBP-2 refers to the Ac1-11–
specific TCR transgenic line in which the a and b transgenes are integrated on the X chromosome.
*The peptide for which the TCR is specific.
‡The class II molecule for which the TCR is restricted.
§The ratio of CD41 cell to CD81 cells. Normal ratio is 2:1.
iThe extent of the thymic abnormality observed as determined by hematoxylin and eosin staining.
¶Whether T cells in the periphery undergo AICD after soluble peptide administration.
**Whether a decline in the number of CD41 T cells in the periphery occurs after soluble peptide administration.
‡‡Th subset induced in peripheral CD41 T cells after soluble low dose (or low affinity) peptide administration.
§§Th subset induced in peripheral CD41 T cells after soluble high dose (or affinity) peptide administration.
i iBackground strain on which experiments were performed.
¶¶Experiments were performed in vitro (38).
***At very low doses, Th2 responses were observed (38).
nd, not determined.587 Pearson et al.
Proliferative Responses Are Enhanced after Peptide Injec-
tion. The proliferative responses of T cells from lymph
nodes from TCR trangenic mice treated with soluble PBS,
Ac1-11, Ac1-11[4A], or Ac1-11[4Y] cultured with irradi-
ated nontransgenic syngeneic splenocytes were enhanced
after peptide treatment through day 2 (Fig. 2). In some ex-
periments, proliferative responses increased with the affin-
ity of the peptide for I-Au (data not shown). Similar results
were found when splenocytes were cultured, except that cells
from Ac1-11[4Y]–injected mice proliferated less well than
or about equal to those from PBS-injected mice (data not
shown). Approximately 60% of CD41 T cells from lymph
nodes from PBS-injected TCR transgenic mice fluxed cal-
cium in response to Ac1-11 presented by nontransgenic
syngeneic splenocytes; 24 h after injection, up to 90% of
CD41 T cells from lymph nodes from mice injected with
either Ac1-11 or Ac1-11[4A] fluxed calcium, whereas only
20–30% of CD41 T cells from mice injected with Ac1-
11[4Y] fluxed calcium (data not shown). By 48 h, how-
ever, the number of cells from Ac1-11[4Y]–injected mice
that fluxed calcium was equal to that of cells from PBS-
injected mice, and both lymph node cells and splenocytes
from Ac1-11–, Ac1-11[4A]–, and Ac1-11[4Y]–injected
mice proliferated in an enhanced fashion (data not shown
and Fig. 2). These results suggest that only Ac1-11[4Y] in-
duces a transient hyporesponsiveness in the first 24 h and
that this can be overcome by the presence of irradiated an-
tigen presenting cells. By day 6, T cells from peptide-injected
mice responded equally to those from PBS-injected mice,
indicating that peptide-injection does not induce any long-
term anergy (Fig. 2).
The CD41 T Cell Population Does Not Decrease after Pep-
tide Injection. Despite the fact that T cells are hyperre-
sponsive after peptide injection, the total number of CD41
T cells increased only 1.5–2-fold over those of PBS-
injected controls by day 2 and 3, and no significant net
changes in the numbers of CD41 T cells in the spleen or
the lymph nodes were detected by day 6 (Fig. 3). When
TCR transgenic mice were given four daily doses of 24 mg
per dose, on average there was approximately a two- to
threefold increase in the number of CD41 T cells by day 6
(data not shown). Thus, significant numbers of responsive
Ac1-11–specific T cells remain in the periphery, unlike
CD41 T cells in the 2B4, HNT-TCR, and DO11.10 TCR
transgenic systems after peptide injection (15, 16, 35). Pre-
liminary results using TCR transgenic mice on the B10.PL
background indicate that each of the three peptides are able
to induce CD41 deletion, the degree of which correlates
with the peptide affinity for the MHC (data not shown),
suggesting that genetic background is important in deter-
mining the extent of peripheral deletion. In both the PL/J
and B10.PL backgrounds, the numbers of CD81 T cells, B
cells, and macrophages do increase, however, by approxi-
mately twofold (data not shown). Presumably, CD81 T
cells are activated through cytokines produced by the CD41
T cells, whereas B cells and macrophages are activated through
interaction of the TCR with peptide/I-Au complex.
T Cell Death in the Periphery after Peptide Injection. Despite
the lack of significant reduction in the numbers of CD41 T
cells in TCR transgenic mice on the PL/J background,
apoptotic cells are detected in lymph nodes 24 h after in-
jection of peptide (Fig. 4). The amount of apoptosis corre-
lates with the affinity of the peptide such that Ac1-11 in-
duces the least amount of apoptosis, Ac1-11[4A] induces an
intermediate level, and Ac1-11[4Y] induces the greatest
degree of apoptosis. Thus, T cells are apparently dying off
rapidly enough to counteract any increase due to prolifera-
tion. Activation-induced cell death (AICD) accompanied
by cytokine production was detected at 500 mM Ac1-11,
100 mM Ac1-11[4A], and 20 mM Ac1-11[4Y] in purified
CD41 T cells cultured in vitro (data not shown). These
data differ from those of Critchfield et al., who detected
AICD of Ac1-11–specific T cells at 100 mM MBP (9). T cells
from our MBP TCR transgenic mice may have a higher
threshold for activation-induced apoptosis due to a lower
level of TCR expression on these T cells compared with
the level on T cells from those TCR transgenic mice stud-
ied by Critchfield et al. (9).
Table 2. Median fluroescent Intensity of Vb8.2, CD69, CD25, 
CD62L, and CD44 on CD41 T Cells from Lymph Nodes after 
Injection of 2.4 mg of Soluble Peptide
Treatment 4 h 24 h 72 h 144 h
Vb8.2
PBS 24.8 19.9 30.1 17.4
Ac1-11 24.1 19.3 26.4 17.3
Ac1-11[4A] 10.6 18.0 27.3 16.7
Ac1-11[4Y] 8.2 7.7 30.9 14.1
CD69
PBS 0.5 0.5 0.7 0.4
Ac1-11 31.6 15.2 1.0 0.5
Ac1-11[4A] 33.0 27.0 1.0 0.4
Ac1-11[4Y] 32.8 39.6 1.2 0.4
CD25
PBS 0.5 0.4 0.7 0.4
Ac1-11 10.1 4.6 1.9 0.7
Ac1-11[4A] 9.4 13.1 1.4 1.0
Ac1-11[4Y] 8.5 25.4 1.2 0.5
CD62L
PBS 24.0 16.5 35.0 23.6
Ac1-11 1.7 4.2 25.9 16.7
Ac1-11[4A] 1.2 3.5 29.4 19.2
Ac1-11[4Y] 1.4 2.7 58.4 17.9
CD44
PBS 2.2 2.5 6.9 3.4
Ac1-11 2.0 4.0 23.0 8.4
Ac1-11[4A] 2.2 5.9 29.3 9.3
Ac1-11[4Y] 2.1 4.8 16.3 8.4588 Apoptosis and Th2 Responses Correlate with Peptide Affinity for MHC
Figure 2. Peripheral T cells from mice injected with Ac1-11, Ac1-11[4A], or Ac1-11[4Y] hyperproliferate for the first 48 h after injection, but prolif-
erate approximately as well as those from PBS-injected mice by day 6. The proliferative responses to Ac1-11, Ac1-11[4A], and Ac1-11[4Y] of cells from
PBS-injected mice (closed squares), Ac1-11–injected mice (open squares), Ac1-11[4A]–injected mice (closed circles), and Ac1-11[4Y]–injected mice (open cir-
cles) were determined in vitro as described in Materials and Methods.
Figure 3. No net change in
the numbers of CD41 T cells in
the periphery is observed after
peptide injection. The numbers
of CD41 and CD81 cells from
lymph nodes and spleen from
TCR transgenic mice injected
with PBS, Ac1-11, Ac1-11[4A],
or Ac1-11[4Y] are shown 1, 2,
and 6 d after a single administra-
tion of 2.4 mg of peptide. Black
bars represent the numbers of
CD41 T cells in the spleen, dark
cross-hatched bars represent the
numbers of CD41 T cells in
lymph nodes, shaded bars repre-
sent the numbers of CD81 T
cells in the spleen, and light
cross-hatched bars represent the numbers of CD81 T cells in the lymph nodes. Results are pooled from three experiments for days 1 and 6, and two ex-
periments for day 2. In one experiment from day 3, CD41 T cells had increased in number by 1.5–2-fold in peptide-injected mice (data not shown).589 Pearson et al.
Figure 4. Soluble peptide induces apoptosis in lymph nodes. Sections from brachial or inguinal lymph nodes from Ac1-11–specific TCR transgenic
mice removed 24 h after intravenous injection with (A) PBS, (B) 2.4 mg of Ac1-11, (C) 2.4 mg of Ac1-11[4A], and (D) 2.4 mg of Ac1-11[4Y]. Apop-
totic cells were visualized using the TUNEL reaction as described in Materials and Methods section and appear as dark spots.590 Apoptosis and Th2 Responses Correlate with Peptide Affinity for MHC
Expression of Fas, Fas Ligand, and TNF-a by CD41 T
Cells. Peripheral T cells have been shown to be deleted
after soluble antigen (37, 38) or anti-CD3 (39) exposure
through the Fas/FasL and TNF/TNFR pathways. To as-
certain whether molecules involved in these pathways can be
induced in the MBP TCR system, we compared the levels
of Fas, FasL, membrane TNF, and lymphotoxin-ab on
CD41 T cells from the MBP-specific TCR transgenic line to
those from an influenza hemagglutinin (HA)–specific TCR
transgenic line (HNT TCR; reference 16) in which up to
80% of CD41 T cells are deleted after soluble peptide treat-
ment. Splenocytes from each type of transgenic line were
cultured in vitro with their respective cognate peptides.
Both Fas and FasL levels are comparable to those seen in
the HA-specific TCR transgenic system (Fig. 5). Lower
levels of membrane TNF and LTab were detected on
CD41 MBP-specific T cells activated with Ac1-11 in vitro.
The levels, however, are at least half of those detected on
HNT CD41 T cells activated in vitro with HA peptide
(Fig. 5).
Cytokine Profiles of Surviving T Cells Differ with Affinity of
Peptide. Since a large population of antigen-responsive T
cells survive the single injection of Ac1-11, Ac1-11[4A], or
Ac1-11[4Y], we examined whether these peptides differed
in induction of T helper subsets. TCR transgenic spleen
cells when cultured in vitro with 100 mM Ac1-11[4A] or
Ac1-11[4Y] (the concentration at which T cells proliferate
equally) produce .200 U/ml IL-2, ,50 ng/ml IFN-g,
and little or no detectable IL-4 or IL-10, which is consis-
tent with a Th0 profile (Fig. 6). Lymph node cells (105)
cultured with irradiated syngeneic splenocytes (5 3 105)
displayed similar cytokine profiles (data not shown). Within
24 h after injection of 2.4 mg of peptide, spleen or lymph
node cells from Ac1-11– or Ac1-11[4A]–injected mice
produce more IL-2 and up to 10 times more IFN-g. Little
or no IL-4 is detectable, and ,1 ng/ml IL-10 is produced
(Fig. 6 A). In contrast, cells from Ac1-11[4Y]–injected mice
make the least amount of IL-2, IFN-g at levels comparable
to those produced by cells from naive mice, detectable lev-
els of IL-4 (up to 1 ng/ml), and 2–6 times more IL-10 than
that produced by cells from Ac1-11– and Ac1-11[4A]–
injected mice (Fig. 6 A). By day 6, IFN-g production was
comparable between the different treatment groups. Cells
from Ac1-11[4Y] consistently produce the least amount of
IFN-g. The amount of IL-4 or IL-10 produced increased
with the affinity of the peptide for I-Au (Fig. 6 B). Thus, a
single dose of low or medium affinity peptides, Ac1-11 and
Ac1-11[4A], induces differentiation into the Th1 subset,
while a single dose of a high affinity peptide, Ac1-11[4Y],
induces differentiation into the Th2 subset. Similar results
were obtained after a single dose of 240 mg of peptide (data
not shown).
To test whether any of these cytokine responses were the
result of differences in APC activation induced in vivo by
peptide administration, CD41 T cells were purified (.95%)
from lymph nodes from mice injected four times with 600 mg
of Ac1-11, 600 mg of Ac1-11[4A], or 24 mg of Ac1-
11[4Y], and stimulated in vitro with irradiated nontrans-
genic splenocytes. The cytokine profiles were very similar
to those derived from stimulation of whole lymph node
Figure 5. CD41 T cells from MBP-specific TCR transgenic mice express less membrane TNF-a and LT-ab than do those from HA-specific TCR
transgenic mice. Expression of CD69, Fas, FasL, mTNF, and LT-ab on splenocytes from either the MBP-specific TCR transgenic line cultured with 50
mM Ac1-11 (Ac1-11) or the hemagglutinin-specific TCR transgenic line (HA) cultured in vitro with 0.2 mg/ml HA peptide 126-138 for 48 h. Live cells
from the 48-h cultures were collected on a Ficoll gradient and washed two times. Cells were then stained with a biotinylated antibody to CD69, a phy-
coerythrin-conjugated antibody to Fas, or Fas/Fc, TNFR/Fc, or LT-bR/Fc fusion proteins as described in Materials and Methods. Histograms display
only large, blasting cells as determined by forward scatter. For CD69 and Fas, dashed lines in plots indicating levels of CD69 or Fas, respectively, of naive
cells from PBS-injected MBP-specific TCR transgenic mice. For FasL, mTNF, and LT-ab expression, dashed lines indicate fluorescence intensity of cells
incubated with only the biotinylated secondary antibody and streptavidin-conjugated Texas red as a negative control.591 Pearson et al.
cells with irradiated splenocytes as APCs, indicating that
any differences lie in the T cells rather than in APCs (data
not shown).
T Helper Differentiation In Vitro by Ac1-11, Ac1-11[4A], or
Ac1-11[4Y]. To ascertain whether Ac1-11 and Ac1-11
[4A] uniformly induce Th1 differentiation, and whether
Ac1-11[4Y] uniformly induces Th2 differentiation, the cy-
tokine profiles of purified naive CD41 T cells in response
to a secondary stimulation after a primary stimulation in
vitro with various doses of either Ac1-11, Ac1-11[4A], or
Ac1-11[4Y] were determined. Ac1-11 induced primarily
Th1 type responses, whereas Ac1-11[4A] and Ac1-11[4Y]
induced both Th1 and Th2 type responses, depending on
the dose of peptide in the primary stimulation (Fig. 7). IL-2
production was inversely correlated with the concentration
of peptide in the primary stimulation. Both high and low
concentrations of the three peptides induced the most IFN-g,
with the exception that Ac1-11[4Y], regardless of dose, did
not induce a large IFN-g response. IL-4 production was
highest at intermediate concentrations, corresponding to those
that induced the least amount of IFN-g. IL-10 production
of cells stimulated by Ac1-11 in the primary culture was
detected only in cells activated by the highest concentra-
tion of Ac1-11. IL-10 production by cells stimulated by
Ac1-11[4A] and Ac1-11[4Y] followed a dose curve–response
similar to that of IL-4 production.
In general, strong Th1 responses were induced at low
concentrations, whereas Th2 responses were induced at high
concentrations. Furthermore, the dose–response curves for
each peptide were shifted in correlation with their affinity for
I-Au such that about 5–25-fold more Ac1-11 than Ac1-11
[4A] was required to induce the least amount of IFN-g and
the most IL-4, whereas approximately fivefold more Ac1-11
[4A] than Ac1-11[4Y] was required to induce a strong Th2
response. These experiments emphasize that the ability to
induce a specific Th response correlates with the dose and
Figure 6. Cytokine profiles of splenocytes from mice injected with PBS, Ac1-11, Ac1-11[4A], or Ac1-11[4Y] 1 d after administration. Increasing
amounts of Th2 type cytokines IL-4 and IL-10 were detected, while decreasing amounts of the Th1 type cytokine IFN-g were detected depending on
the peptide injected. Cells were cultured at 3–5 3 105 cells per well in 96-well round-bottom plates with either medium only, Ac1-11, Ac1-11[4A], or
Ac1-11[4Y]. Supernatants were collected 45–52 h later, and the amount of IL-2, IFN-g, IL-4, and IL-10 was determined by ELISA. Black bars, cytokine
production in response to Ac1-11 stimulation; shaded bars, cytokine production in response to Ac1-11[4A]; and cross-hatched bars, cytokine production
in response to Ac1-11[4Y]. (A) Cytokine profiles of splenocytes from mice injected with PBS or 2.4 mg of Ac1-11, Ac1-11[4A], or Ac1-11[4Y] 1 d after
administration. (B) Cytokine profiles of splenocytes from mice injected with PBS or 2.4 mg of Ac1-11, Ac1-11[4A], or Ac1-11[4Y] 6 d after administra-
tion. Similar to day 1, increasing amounts of Th2 type cytokines IL-4 and IL-10 were detected, while decreasing amounts of the Th1 type cytokines IL-2 and
IFN-g were detected depending on the peptide injected. No cytokines were detected in supernatants from cells incubated with medium only.592 Apoptosis and Th2 Responses Correlate with Peptide Affinity for MHC
the affinity of the peptide for the MHC, and they show
that Ac1-11[4Y] is much more potent at inducing Th2
type responses in vitro, paralleling our findings in vivo.
Inhibition of MHC-Peptide-TCR Interaction In Vitro by
Anti–class II Antibody. The different abilities of each of
the three peptides to induce Th1 and Th2 responses may
stem from the individual affinity of the peptide–MHC for
the TCR or from differing numbers of peptide–MHC
ligands interacting with TCR at the site of APC–T cell con-
tact. To differentiate between these possibilities, two differ-
ent concentrations of anti–class II antibody (10-3.6) were
added to three different doses of Ac1-11[4Y] in the pri-
mary stimulation. At 12.5 mg/ml, 10-3.6 reduced the pri-
mary IL-2 production by 30–50%, whereas 3.125 mg/ml
10-3.6 reduced the primary IL-2 production by 5–30%
(Fig. 8 A). Interestingly, suppression of the primary re-
sponse by anti–class II antibody at 12.5 mg/ml induced
stronger Th2 responses in the secondary stimulation at all
three primary doses of Ac1-11[4Y] than did addition of no
antibody (Fig. 8, B and C). Addition of 3.125 mg/ml 10-
3.6 in the primary stimulation correlated with about two-
fold increased production of both IFN-g and IL-4 in the
secondary stimulation but did not change the ratio of IFN-g
to IL-4. In contrast, addition of 3.125 mg/ml 10-3.6 to a
primary stimulation of 50 mM Ac1-11 inhibited primary
IL-2 production by 30% and correlated with increases in
IFN-g responses of 20-fold in the secondary stimulation,
while addition of 12.5 mg/ml 10-3.6 inhibited primary IL-2
production by z75% and correlated with increases in IFN-g
production of .200-fold in the secondary stimulation (data
not shown). The production of IL-4 was similar between
12.5 mg/ml, 3.125 mg/ml, and no antibody in the Ac1-11
Figure 7. The induction of Th1 and Th2 type cells in vitro. Lymph node cells from an MBP-specific TCR transgenic mouse were stained with CD8,
B220, Mac-1, CD69, and CD44, and the negative cells were collected by flow cytometry as naive, CD41 T cells (reanalysis of cells by flow cytometry in-
dicated a population .98% CD41). These cells were cultured in vitro at a concentration of 105 CD41 cells and 106 irradiated nontransgenic syngeneic
splenocytes per well in 24-well plates with varying concentrations of Ac1-11, Ac1-11[4A], or Ac1-11[4Y]. 10 d later, cells were washed several times and
restimulated at a concentration of 5 3 104 T cells plus 3 3 105 irradiated splenocytes per well in 96-well round-bottom plates with 10 mM Ac1-11, Ac1-
11[4A], or Ac1-11[4Y]. Supernatants were collected at 48 h, and cytokines were detected by ELISA. Black bars, cytokine response to Ac1-11 in second-
ary challenge; shaded bars, cytokine response to Ac1-11[4A] in secondary challenge; cross-hatched bars, cytokine response to Ac1-11[4Y] in secondary
challenge. In general, Ac1-11 induced Th1 type responses regardless of primary concentration, Ac1-11[4A] induced Th2 type responses at high concen-
trations and Th1 type responses at low concentrations, and Ac1-11[4Y] induced primarily Th2 type responses, except at the lowest two doses. nd, not de-
termined. Previous experiments indicated that too few live cells were recovered at the doses for which cytokine levels were not determined to test a sec-
ondary response.593 Pearson et al.
primary stimulation. These data indicate that the difference
in affinity between Ac1-11 and Ac1-11[4Y] accounts for
their differential ability to induce Th1 or Th2 responses.
Addition of IL-4 or Anti–IL-4 Antibody to Primary Stimula-
tions. Addition of IL-4 to Ac1-11 or Ac1-11[4Y] primary
stimulations in vitro induced strong Th2 responses regard-
less of the dose of Ac1-11 or Ac1-11[4Y] (Table 3). Con-
versely, addition of anti–IL-4 antibody (BVD-4) to the pri-
mary stimulations induced strong Th1 responses regardless
of the dose of peptide in the primary stimulation (Table 3).
These results parallel other findings that show that exoge-
nous IL-4 will induce Th2 responses, whereas anti–IL-4
will induce Th1 responses (1). Thus, despite the results re-
ported above, neither Ac1-11 nor Ac1-11[4Y] carries an
intrinsic quality that prevents Th2 or Th1 responses, re-
spectively. When Ac1-11[4Y] is administered to TCR trans-
genic mice given 200 mg of anti–IL-4 on days 21 and 0 or
to mice homozygous for a disrupted IL-4 gene, however,
production of IL-2, IFN-g, and IL-10 resembles that seen
in normal TCR transgenic mice (data not shown), indicat-
ing that endogenous IL-4 production in vivo is not solely
responsible for the Th2 responses that are induced after sol-
uble peptide administration.
Anti–B7-2 Downregulates In Vivo Differentiation of Th2 Re-
sponses by Ac1-11[4Y]. Previous studies have indicated
that co-stimulatory molecules influence T helper subset
differentiation (see references 46 and 47). To test whether
blocking upregulation of B7-2 on B cells would downreg-
ulate Th2 differentiation observed after Ac1-11[4Y] admin-
istration in vivo, 100 mg of anti–B7-2 antibody was given on
day 21, and both antibody and 2.4 mg of Ac1-11[4Y]
were given on day 0. 1 d after peptide administration, B7-1
was upregulated on macrophages, but not on B cells in
both PBS- and anti–B7-2–treated mice given Ac1-11[4Y].
B7-2, in contrast, was upregulated on B cells in mice given
Ac1-11[4Y] only, but not in mice given both Ac1-11[4Y]
and anti–B7-2 antibody (Fig. 9 A). IL-2 production by
splenocytes from Ac1-11[4Y]–treated mice having either
no treatment or anti–B7-2 did not show any significant dif-
ferences. In contrast, IFN-g production by cells from anti–
B7-2– and Ac1-11[4Y]–treated mice increased by approxi-
mately twofold, while IL-4 and IL-10 production decreased
two- to fourfold relative to that by cells from Ac1-11[4Y]–
treated mice (Fig. 9 B).
Discussion
Many studies have demonstrated the benefits of peptide
therapy of autoimmune disease, yet little is understood
about the precise mechanisms that underlie these benefits.
Several studies have suggested that autoimmune T cells are
deleted, anergized, or switched from a deleterious Th sub-
Figure 8. The effect of the ad-
dition of anti–class II antibody
(10-3.6) on in vitro differentia-
tion of naive TCR transgenic
mice T cells by 50, 5, and 0.5
mM Ac1-11[4Y]. Black bars rep-
resent responses of T cells cul-
tured with 12.5 mg/ml 10-3.6
and Ac1-11[4Y], shaded bars
those of T cells cultured with
3.125 mg/ml 10-3.6 and Ac1-
11[4Y], and cross-hatched bars
those of T cells cultured with
Ac1-11[4Y] alone. Sorted naive T
cells were cultured in 24-well
plates with irradiated splenocytes as APCs with various amounts of 10-3.6 and Ac1-11[4Y]. IL-2 production in the primary stimulation was determined
on culture supernatant 48 h after initial stimulation with Ac1-11[4Y] and 10-3.6. After a total of 7 d, viable cells were then washed and cultured with 10
mM Ac1-11[4Y] or medium only in 96-well round-bottom plates at 5 3 104 cells/well and 5 3 105 APCs/well for 48 h. IFN-g and IL-4 production in
the secondary stimulation was determined as described. (A) IL-2 production by naive T cells in the primary stimulation is decreased by addition of 10-3.6.
(B) IFN-g production by T cells in the secondary stimulation does not change significantly by addition of 10-3.6. (C) IL-4 production by T cells in the
secondary stimulation increases 2–20-fold, depending on the initial concentration of Ac1-11[4Y].
Table 3. Production of IFN-g and IL-4 in Secondary Cultures of 
T Cells Stimulated with Varying Doses of Ac1-11 or Ac1-11[4Y] 
with or without Exogenous IL-4 or Anti–IL-4 Antibody
Ac1-11
Condition
IFN-g IL-4
Primary dose
500 mM5   m M 500 mM5   m M
ng/ml
None 4.23 22.82 0.70 0.18
IL-4 0.08 ,0.05 5.11 5.21
Anti–IL-4 20.97 7.38 ,0.03 ,0.03
Ac1-11[4Y]
Condition
Primary dose
500 mM5   m M 0.05 mM500 mM5   m M 0.5 mM
ng/ml
None 7.38 0.53 3.39 0.31 1.30 2.33
IL-4 0.04 0.39 0.10 5.80 9.70 4.10
Anti–IL-4 6.08 16.71 3.91 ,0.03 ,0.03 0.06594 Apoptosis and Th2 Responses Correlate with Peptide Affinity for MHC
set to a protective one (6–9, 13, 14, 40). We have devel-
oped a transgenic model in which most T cells express a T cell
receptor specific for the NH2-terminal peptide of myelin
basic protein, Ac1-11, and restricted to the class II MHC
molecule I-Au, as a model for easily following potentially
encephalitogenic T cells in the periphery after soluble pep-
tide therapy. Injection of a single dose of Ac1-11, Ac1-
11[4A], or Ac1-11[4Y] deletes CD41CD81 DP thymo-
Figure 9. The effect of anti–B7-2 on the in vivo expression of B7-1 and B7-2 and the development of Th2 responses in vivo after injection of Ac1-
11[4Y]. TCR transgenic mice were injected intraperitoneally with either PBS or 100 mg of anti–B7-2 antibody GL-1 on days 21 and 0. On day 0, mice
were injected intravenously with either PBS or 2.4 mg of Ac1-11[4Y], and mice were killed on day 1. (A) The expression of B7-1 and B7-2 on B cells
and macrophages was determined as described in Materials and Methods. Solid lines, expression of B7-1 or B7-2 on cells from mice injected intrave-
nously with PBS; dashed lines, expression on cells from mice injected with Ac1-11[4Y]. B7-1 was upregulated on macrophages from Ac1-11[4Y]–
injected mice treated intraperitoneally with either PBS or anti–B7-2, while B7-2 was upregulated on B cells from Ac1-11[4Y]–injected mice given PBS
intraperitoneally, but not on cells from Ac1-11[4Y]–injected mice given anti–B7-2 intraperitoneally. (B). The cytokine profile of splenocytes in response
to 10 mM Ac1-11, Ac1-11[4A], or Ac1-11[4Y] was determined by ELISA as described. Black bars, cytokine response to Ac1-11 in secondary challenge;
shaded bars, cytokine response to Ac1-11[4A] in secondary challenge; cross-hatched bars, cytokine response to Ac1-11[4Y] in secondary challenge. IL-2
production was similar between mice given PBS or Ac1-11[4Y] intravenously, regardless of antibody treatment. IFN-g production was increased approxi-
mately twofold in mice given both Ac1-11[4Y] and anti–B7-2 over that of cells from mice given only Ac1-11[4Y], while IL-4 and IL-10 production by
cells from mice given both Ac1-11[4Y] and anti–B7-2 was reduced by about two- to fourfold relative to production by cells from mice given Ac1-
11[4Y] only.595 Pearson et al.
cytes and activates peripheral T cells. Although AICD was
detected in lymph nodes 24 h after peptide injection, the
numbers of CD41 T cells in the periphery did not decline.
Surviving cells from peptide-injected mice proliferated in
vitro and had differing cytokine profiles. Specifically, pep-
tides with low and intermediate affinities for the MHC,
Ac1-11, and Ac1-11[4A], induced Th1 responses, while
Ac1-11[4Y], which had the highest affinity for the MHC,
induced a Th2 response. In addition, the thymus of both
lines have no discrete cortex and medulla, an observation
first noted in two other TCR transgenic mice that have the
same MBP specificity (33a).
We observed similar thymic abnormalities in three other
class II–restricted TCR transgenic lines that have a high
CD4/CD8 ratio, indicating that the skewing toward a
CD4 population, rather than the specificity of the TCR,
results in the thymic abnormality. The reduced cortical size
and disorganized medullary epithelium may be due to the
over- or underproduction of a growth factor needed for
normal organization of the cortex and medulla. A paucity
of DP thymocytes, which normally reside in the cortex,
and/or an overabundance of CD41 SP cells, which reside
in the medulla, could account for the under- or overpro-
duction of such a factor.
Despite this abnormality, however, deletion of DP thy-
mocytes was readily induced by injection of soluble pep-
tide, as has been shown for other TCR transgenic systems
(34, 35). The efficacy of deletion correlated well with the
affinity of the peptide for the MHC. In a previous study us-
ing similar TCR transgenic mice, Ac1-11 was unable to in-
duce any significant deletion (41). Our results may differ
because (a) a higher dose of Ac1-11 was used in our studies
and/or (b) there are fewer DP cells in our TCR transgenic
mice. Our results and those of Liu et al. (41) reflect the im-
portance of affinity of the selecting peptide for the MHC.
Furthermore, the fact that Ac1-11 is a relatively poor
mediator of negative selection provides support for the
hypothesis that low affinity ligands may allow self-reactive T
cells to mature and emigrate from the thymus into the pe-
riphery, as has been suggested (41).
The nature of the TCR-peptide-MHC interaction plays
a critical role in the induction of deletion in the thymus,
as it does in activation of the T cell in the periphery. Mul-
tiple stimulations through the TCR are thought to first ac-
tivate T cells and then result in apoptosis or AICD (22). Al-
though apoptosis is detected within 24 h after injection of
Ac1-11, Ac1-11[4A], or Ac1-11[4Y], many cells survive.
In the case of Ac1-11, the relative resistance to efficient de-
letion in the periphery of T cells from MBP TCR mice may
stem from the immeasurably short half-life of the Ac1-11/
I-Au complex (12). Thus, these T cells may receive enough
repetitive stimulations through the TCR to become acti-
vated, but only a small percentage receive a large enough
signal to apoptose. This phenomenon is highlighted by an-
other study in which 1.4 mg of Ac1-11 given eight times
intravenously was required to delete Ac1-11–specific
trangenic T cells from a different TCR transgenic mouse in a
transfer system (9). The Ac1-11[4A]/I-Au complex has a
longer half-life of z10 min (12), and accordingly, more
apoptotic cells are observed in the lymph node 24 h after
Ac1-11[4A] injection. Ac1-11[4Y], which when com-
plexed to I-Au has a half-life of at least 4 h (12), stimulates
the largest amount of apoptosis, although a significant frac-
tion still survives. Because there are no net decreases in the
numbers of CD41 T cells in the periphery after injection of
any of the three peptides, we conclude that the number of
cells that are deleted through AICD is replaced by an ap-
proximately equal number of cells, presumably through
proliferation in vivo. Thus, the proliferative and apoptotic
responses induced in vivo by soluble peptide correlate di-
rectly with the peptide affinity for the MHC, resulting in
no net loss of CD41 T cells in the periphery.
Our findings that cell numbers do not decline after a sin-
gle dose of peptide differ from other studies using similar
regimens (15, 16, 35, 37). This discrepancy cannot simply
be a result of these T cells developing a thymus that has an
abnormal architecture, as peripheral CD41 T cells are de-
leted in other TCR transgenic systems that have a similar
thymic abnormality (see Table 1). One possible explanation
is that genetic background may be important in determin-
ing the extent of deletion, as preliminary data indicate that
after peptide injection, the number of CD41 T cells de-
clines in direct correlation with the affinity of the peptide
for the MHC in our MBP-specific TCR transgenic mice
on the B10.PL background rather than the PL/J back-
ground.
The surviving cells from peptide-injected mice do not
differ in their in vitro proliferative response but do differ in
their Th subset. Differentiation into Th1 or Th2 cells is in-
fluenced by the nature and level of expression of peptide/
MHC complexes (42–45), the costimulatory molecules
with which the T cells interact (46, 47), and the route and
dose of the antigen (1). In addition to these previous stud-
ies, we have shown that the induction of Th2 type cyto-
kines IL-4 and IL-10 correlates with the peptide affinity for
the MHC both in vivo and in vitro. These observations
agree with other studies in which high antigen dose leads to
Th2 type responses, whereas low antigen dose leads to Th1
type responses (42, 43). Our in vivo results differ from re-
cent data that indicate that high affinity analogues of Ac1-11
induce Th1 responses (48). In this study, however, responses
were analyzed after immunization in complete Freund’s ad-
juvant, which is used to induce EAE.
The in vitro data in this study show that the three dis-
tinct peptides, Ac1-11, Ac1-11[4A], and Ac1-11[4Y], induce
different relative levels of IFN-g, IL-4, and IL-10, regard-
less of the primary stimulating dose. Inhibition of MHC-
peptide-TCR interactions by the addition of anti–class II
antibody to primary cultures stimulated with Ac1-11[4Y]
enhanced Th2 responses, whereas addition of antibody to
those stimulated with Ac1-11 enhanced Th1 responses.
These data suggest that the differential ability of these pep-
tides to induce different Th subsets lies within the affinity
of the individual peptide for the MHC. These data also sug-596 Apoptosis and Th2 Responses Correlate with Peptide Affinity for MHC
gest that Ac1-11[4A] and Ac1-11[4Y] may act as altered
peptide ligands (APL), which can stimulate a different type
of T cell response than does the wild-type peptide (49). In
addition to increasing the affinity of the peptide for the
MHC and the half-life of the peptide–MHC complex, the
changes of lysine to alanine and tyrosine at position four in
Ac1-11 may subtly alter the conformation of the peptide
bound to the MHC, altering the affinity of the TCR for
the peptide–MHC complex. Such an altered interaction
could lead to a qualitatively different T cell response, which
in this case would be enhanced stimulatory capacity and
enhanced ability to induce Th2 responses. Other studies
have used APL in treatment (13, 14) or prevention (40) of
EAE and shown that they preferentially induce Th2 type
responses.
How antigen dose affects T helper subset differentiation
is unknown. We have used Ac1-11, Ac1-11[4A], and Ac1-
11[4Y] to vary the effective antigen dose. Our data support
the hypothesis that the individual peptide–MHC complex is
the critical factor in determining Th subset. In fact, however,
affinity as well as concentration, half-life, and TCR affinity
for the peptide–MHC complex determine the actual num-
bers of peptide–MHC complexes and ultimately the effec-
tive antigen dose at any one time. Thus, the addition of a
peptide that has a very low affinity and very short half-life,
such as Ac1-11, results in effective doses that favor Th1
type differentiation, whereas addition of a peptide that has a
very high affinity and very long half-life, such as Ac1-
11[4Y], results in effective doses that favor Th2 type differ-
entiation.
The results presented here provide evidence that increas-
ing the dose or signals through the TCR favors certain
pathways of differentiation. Consequently, weak or strong
signals will favor up- or downregulation of molecules that
influence T helper status. Examples of such molecules are
the co-stimulatory molecules B7-1 and B7-2, which are up-
regulated on B cells and other antigen-presenting cells after
TCR ligation of peptide–MHC complex or encountering
various cytokines (50, 51). One day after injection of peptide
in vivo, the level of expression of B7-2 on B cells increases
with increasing affinity of the peptide. The combination of
upregulation of B7-2 on B cells may be particularly rele-
vant for Th2 responses, as B cells and B7-2 have been
shown separately to induce Th2 responses (46, 47, 52). In
accordance, blocking B7-2 upregulation, but not B7-1, in
Ac1-11[4Y]–injected mice correlates with increased IFN-g
and decreased IL-4 and IL-10 production. Thus, Ac1-
11[4Y] favors upregulation of B7-2 on B cells through a
strong TCR signal which in turn favors Th2 type responses.
B7-1, however, is also upregulated on macrophages from
Ac1-11[4Y]–injected mice, suggesting that B7-2 is not solely
responsible for the development of Th2 responses in vivo.
The presence of IL-4 dominates IFN-g during in vitro
differentiation of T helper subsets (1). The data presented
here suggest that production of endogenous IL-4 is sensi-
tive to the strength of signal through the TCR such that
enough IL-4 dominates during differentiation of T cells re-
ceiving strong signals (Ac1-11[4Y]) but does not during
differentiation of T cells receiving weak signals (Ac1-11).
Although the in vitro experiments show that endogenous
IL-4 is required for secondary IL-4 responses, in vivo ex-
periments using mice with a disrupted IL-4 gene or mice
treated with anti–IL-4 antibody indicate that the presence
of endogenous IL-4 is not required for other features char-
acteristic of Th2 responses, such as the downregulation of
IL-2 and IFN-g and the upregulation of IL-10 by Ac1-
11[4Y]. Thus, differential upregulation of B7-2 and IL-4
by Ac1-11, Ac1-11[4A], or Ac1-11[4Y] represent only
two of many molecules that influence T helper subset dif-
ferentiation in vivo.
In addition to these factors, genetic background plays a
role in whether a Th1 or Th2 response predominates. A
number of studies indicate that T cells from mice on the
B10 background are more likely to develop into Th1 cells,
while those from BALB/c mice are more likely to develop
into Th2 cells (53, 54). This difference has a profound ef-
fect on the outcome of immune responses to autoantigens
and parasites (55, 56). Recent experiments suggest that the
Th2 pathway is the default pathway, and a Th1 type re-
sponse depends on the strength of signaling of IL-12, a po-
tent inducer of Th1 cells, such that BALB/c mice have a
less efficient IL-12 response (57, 58). In addition, IL-1 and
TNF-a, both Th1 type cytokines, are required for maximal
IFN-g production (59). Indeed, B10 mice express higher
endogenous levels of TNF than do BALB/c mice, and LPS-
induced TNF production follows a similar pattern (Cope,
A., and H. McDevitt, unpublished observations). More-
over, production of membrane TNF and LTab on cells
from MBP-specific TCR transgenic mice on the PL/J back-
ground was lower than that seen on cells from HA-specific
TCR transgenic mice on the B10.D2 background. Recent
findings indicate that TNF-a initiates T cell apoptosis in
both the CD81 and CD41 compartments (38, 39). Fur-
thermore, other experiments suggest that Th1 cells are more
susceptible to Fas-induced apoptosis than are Th2 cells
(60). Thus, in our system, the PL/J background may re-
semble the BALB/c background such that IL-12 and TNF
induction may be lower than that found in the B10 back-
ground, leading to stronger Th2 responses that are more
resistant to Fas-induced apoptosis, and less apoptosis medi-
ated by a weaker TNF response.
The induction of tolerance by soluble antigen has long
been observed, but only recently have studies shown that
soluble antigen can induce Th2 responses while suppressing
Th1 type responses (18–21). Although some studies sup-
port the concept that T cells are deleted or anergized after
peptide therapy (6, 8, 41), others have shown that EAE
therapy with MBP or proteolipid protein peptide analogues
that are TCR antagonists induce Th2 type cytokines (13,
14, 40). This is the first study that demonstrates that a pep-
tide with high affinity for the MHC and which efficiently
treats EAE induces both apoptosis and a protective Th2
subset differentiation of autoimmune T cells in vivo. How-
ever, multiple high doses of Ac1-11 and Ac1-11[4A], which
induce Th1 responses in our TCR transgenic mice, can
also treat EAE in nontransgenic mice (6, 7). In these stud-597 Pearson et al.
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